Prophylactic ranitidine treatment in critically ill children - a population pharmacokinetic study

British Journal of Clinical Pharmacology

Volumn 75, Issue 5, 2013, Pages 1265-1276

  Hawwa, Ahmed F ^a   Westwood, Paul M ^a   Collier, Paul S ^a   Millership, Jeffrey S ^a   Yakkundi, Shirish ^a   Thurley, Gillian ^b   Shields, Mike D ^b   Nunn, Anthony J ^c   Halliday, Henry L ^a   Mcelnay, James C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL BELFAST HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Gastro oesophageal reflux; Nonlinear mixed effects modelling; Population pharmacokinetics; Ranitidine; Stress ulcers

Indexed keywords

RANITIDINE;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CRITICALLY ILL PATIENT; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STRESS ULCER;

ADOLESCENT; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PROSPECTIVE STUDIES; RANITIDINE; STOMACH ULCER;

EID: 84876060926     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04473.x     Document Type: Article

References (58)

1. Crill CM, Hak EB. Upper gastrointestinal tract bleeding in critically ill pediatric patients. Pharmacotherapy 1999; 19: 162-180.
2. Reveiz L, Guerrero-Lozano R, Camacho A, Yara L, Mosquera PA. Stress ulcer, gastritis, and gastrointestinal bleeding prophylaxis in critically ill pediatric patients: a systematic review. Pediatr Crit Care Med 2010; 11: 124-132.
3. Lopez-Herce J, Dorao P, Elola P, Delgado MA, Ruza F, Madero R. Frequency and prophylaxis of upper gastrointestinal hemorrhage in critically ill children: a prospective study comparing the efficacy of almagate, ranitidine, and sucralfate. Crit Care Med 1992; 20: 1082-1089.
4. Chaïbou M, Tucci M, Dugas MA, Farrell CA, Proulx F, Lacroix J. Clinically significant upper gastrointestinal bleeding acquired in a pediatric intensive care unit: a prospective study. Pediatrics 1998; 102: 933-938.
5. Cochran EB, Phelps SJ, Tolley EA, Stidham GL. Prevalence of, and risk factors for, upper gastrointestinal tract bleeding in critically ill pediatric patients. Crit Care Med 1992; 20: 1519-1523.
6. Nelson S, Chen E, Syniar GM, Christoffel KK. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Arch Pediatr Adolesc Med 2000; 154: 150-154.
7. Rudolph CD, Mazur LJ, Liptak GS, Baker RD, Boyle JT, Colletti RB, Gerson WT, Werlin SL. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children. J Pediatr Gastroenterol Nutr 2001; 32: S1-31.
8. Vandenplas Y, Hegar B. Diagnosis and treatment of gastro-oesophageal reflux disease in infants and children. J Gastroenterol Hepatol 2000; 15: 593-603.
9. Engelhardt T, Webster NR. Pulmonary aspiration of gastric contents in anaesthesia. Br J Anaesth 1999; 83: 453-460.
10. Ku CM, Ong BC. Postoperative nausea and vomiting: a review of current literature. Singapore Med J 2003; 44: 366-374.
11. Hoyt J. Aspiration pneumonitis: patient risk factors, prevention, and management. J Intensive Care Med 1990; 5: S2-9.
12. 2 antagonists in intensive care unit patients. J Intensive Care Med 1990; 5: S40-43.
13. Marik PE. Stress ulcer prophylaxis: a practical approach. J Intensive Care Med 1999; 14: 1-8.
14. Gardner TB, Robertson DJ. Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterol 2006; 101: 2206-2208.
15. Hing JP, Woolfrey SG, Greenslade D, Wright PMC. Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data. J Pharmacokinet Pharmacodyn 2001; 28: 465-479.
16. Beal SL, Sheiner LB, Boeckmann AJ, NONMEM Users Guides. Ellicott City, MD: Icon Development Solutions, 1989-2006.
17. Holford NH. Wings for NONMEM 2007. Available at http://wfn.sourceforge.net (last accessed 7 February 2012).
18. Wilkins JJ. NONMEMory: a run management tool for NONMEM. Comput Methods Programs Biomed 2005; 78: 259-267.
19. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic / pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
20. Karlsson MO. Model-building diagnostics. DIA Meeting, Philadelphia, PA, 5-6 December 2005.
21. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558-569.
22. Paediatric Formulary Committee. The BNF for Children 2010-2011. London: BMJ Group, 2011.
23. Roberts CJ. Clinical pharmacokinetics of ranitidine. Clin Pharmacokinet 1984; 9: 211-221.
24. Garg DC, Weidler DJ, Eshelman FN. Ranitidine bioavailability and kinetics in normal male subjects. Clin Pharmacol Ther 1983; 33: 445-452.
25. Blumer JL, Rothstein FC, Kaplan BS, Yamashita TS, Eshelman FN, Myers CM, Reed MD. Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease. J Pediatr 1985; 107: 301-306.
26. Kortejärvi H, Yliperttula M, Dressman JB, Junginger HE, Midha KK, Shah VP, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. J Pharm Sci 2005; 94: 1617-1625.
27. GlaxoSmithKline Inc. ZANTAC® Product Monograph: Histamine H2-Receptor Antagonist. Mississauga, ON: GlaxoSmithKline Inc., 2009. Accessed at http://gsk.ca/english/docs-pdf/Zantac_PM_20090804_EN.pdf (last accessed 7 February 2012).
28. Brummel G, Lucking SE. Pharmacology: pharmacokinetics. In: Pediatric Critical Care Study Guide: Text and Review, eds Lucking SE, Maffei FA, Tamburro RF, Thomas NJ London: Springer, 2012; 334-344.
29. Porter RS, Kaplan JL. The Merck Manual Online - Drug Distribution to Tissues. 2010-2011 ed. Readington, NJ: Merck Sharp & Dohme Corp, 2011. Accessed at http://www.merckmanuals.com/professional/clinical_pharmacology/pharmacokinetics/drug_distribution_to_tissues.html (last accessed 7 February 2012).
30. Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill, 2006.
31. Ilett KF, Nation RL, Tjokrosetio R, Thompson WR, Oh TE, Cameron PD. Pharmacokinetics of ranitidine in critically ill patients. Br J Clin Pharmacol 1986; 21: 279-288.
32. Lugo RA, Harrison AM, Cash J, Sweeley J, Vernon DD. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. Crit Care Med 2001; 29: 759-764.
33. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-332.
34. Lugo RA, Harrison AM, Cash J, Sweeley J, Vernon DD. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005; 7: E475-487.
35. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 2000; 50: 125-134.
36. Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol 2003; 43: 698-710.
37. Allegaert K, Anderson BJ, Cossey V, Holford NH. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 2006; 61: 39-48.
38. Wiest DB, O'Neal W, Reigart JR, Brundage RC, Gillette PC, Yost RL. Pharmacokinetics of ranitidine in critically ill infants. Dev Pharmacol Ther 1989; 12: 7-12.
39. Orenstein SR, Blumer JL, Faessel HM, McGuire JA, Fung K, Li BUK, Lavine JE, Grunow JE, Treem WR, Ciociola AA. Ranitidine, 75mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-esophageal reflux. Aliment Pharmacol Ther 2002; 16: 899-907.
40. Wells TG, Heulitt MJ, Taylor BJ, Fasules JW, Kearns GL. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. J Clin Pharmacol 1998; 38: 402-407.
41. Garg DC, Baltodano N, Jallad NS, Perez G, Oster JR, Eshelman FN, Weidler DJ. Pharmacokinetics of ranitidine In patients with renal failure. J Clin Pharmacol 1986; 26: 286-291.
42. Koch KM, Liu M, Davis IM, Shaw S, Yin Y. Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment. Eur J Clin Pharmacol 1997; 52: 229-234.
43. Van Hecken AM, Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ. Ranitidine-single dose pharmacokinetics and absolute bioavailability in man. Br J Clin Pharmacol 1982; 14: 195-200.
44. Pérez JF, Juárez-Olguín H, Pérez CF, Pérez-Guillé G, Guillé-Pérez A, Camacho-Vieyra A, Toledo-López A, Carrasco-Portugal M, Lares-Asseff I. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int 2003; 20: 485-494.
45. Yin OQP, Tomlinson B, Chow AHL, Chow MSS. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine. Clin Pharmacokinet 2003; 42: 179-192.
46. Garg DC, Eshelman FN, Weidler DJ. Pharmacokinetics of ranitidine following oral administration with ascending doses and with multiple-fixed doses. J Clin Pharmacol 1985; 25: 437-443.
47. Ammon S, Treiber G, Kees F, Klotz U. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobactor pylori. Aliment Pharmacol Ther 2000; 14: 759-766.
48. Olguín HJ, Flores J, Pérez G, Hernández G, Flores C, Guillé A, Camacho A, Toledo A, Carrasco M. Effect of food consistency on the pharmacokinetics of ranitidine in healthy volunteers. J Pharm Technol 2002; 18: 178-181.
49. Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn 2004; 31: 109-134.
50. Rigby-Jones AE, Nolan JA, Priston MJ, Wright PM, Sneyd JR, Wolf AR. Pharmacokinetics of propofol infusions in critically ill neonates, infants, and children in an intensive care unit. Anesthesiology 2002; 97: 1393-1400.
51. Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure. An updated review. Clin Pharmacokinet 1988; 15: 94-113.
52. Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettilä V. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thorac Surg 2006; 81: 542-546.
53. Rigden SPA, Barratt TM, Dillon MJ, De Leval M, Stark J. Acute renal failure complicating cardiopulmonary bypass surgery. Arch Dis Child 1982; 57: 425-430.
54. Gharehbaghi MM, Peirovifar A. Evaluating causes of acute renal failure in newborn infants. Pak J Med Sci 2007; 23: 877-880.
55. Myers JD, Hickam JB. An estimation of the hepatic blood flow and splanchnic oxygen consumption in heart failure. J Clin Invest 1948; 27: 620-627.
56. Stenson RE, Constantino RT, Harrison DC. Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation 1971; 43: 205-211.
57. Leithe ME, Margorien RD, Hermiller JB, Unverferth DV, Leier CV. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation 1984; 69: 57-64.
58. Moffett BS, Mott AR, Nelson DP, Gurwitch KD. Medication dosing and renal insufficiency in a pediatric cardiac intensive care unit: impact of pharmacist consultation. Pediatr Cardiol 2008; 29: 744-748.